**Prior Authorization DRUG Guidelines**

**FLOLAN (epoprostenol)**

Effective Date: 10/20/14
Date Developed: 10/14/14
Last Approval Date: 1/26/16, 1/24/17, 1/23/18

**Description:** Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of arachidonic acid, is a naturally occurring prostaglandin with potent vasodilatory activity and inhibitory activity of platelet aggregation.

**Pre-Authorization Criteria:** Treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms to improve exercise capacity.

**Unlabeled use:** Acute vasodilator testing in PAH.

**Note:** Per VCHCP policy, unlabeled uses are not covered unless specific documentation is submitted. See Policy on Coverage of Prescription Medications for Off-Label Use.

**Dosing:** By continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump: initiate at 2 ng/kg/min; increase by same at greater than 15-minute intervals, observing for side effects (thereafter, mean incremental increase is approximately 2-3 ng/kg/min every three weeks); following dosage adjustments, monitor standing and supine blood pressure and heart rate closely for several hours; temporary peripheral intravenous infusion may be used initially until central access is established.

**How Supplied:** 10 mL vials: 0.5mg (500,000 ng), 1.5 mg (1,500,000 ng); 50 mL sterile diluent

**Contraindications/Warnings:** Contraindicated in patients with congestive heart failure due to severe left ventricular systolic dysfunction; must not be reconstituted or mixed with any other parenteral medications or solutions prior to or during administration; only mix with provided diluent; Initiate epoprostenol in a setting with adequate personnel and equipment for physiologic monitoring and emergency care; based on clinical trials, the acute hemodynamic response to epoprostenol did not correlate well with improvement in exercise tolerance or survival during chronic use;

**Major Adverse Reactions:** Hypotension, dizziness, tachycardia, pallor; rebound pulmonary hypertension after abrupt withdrawal (epoprostenol is metabolized rapidly; even brief interruptions in delivery may result in symptoms associated with rebound pulmonary hypertension)
**Major Drug Interactions:** Additional reductions in blood pressure may occur when *epoprostenol* is administered with diuretics, antihypertensive agents, or other vasodilators; when other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for increased risk of bleeding.

**REFERENCES**


Revision History:

Date Approved by P&T Committee: 10/28/14; QA Committee: 11/25/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 3/12/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>Date</td>
<td>Status</td>
<td>Authors</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>